Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: A systematic review and meta-analysis

JAMA Neurology

Volumn 73, Issue 11, 2016, Pages 1316-1324

  Qin, Xiao Yan ^a   Zhang, Shu Ping ^a   Cao, Chang ^a   Loh, Y Peng ^b   Cheng, Yong ^b  

^a MINZU UNIVERSITY OF CHINA   (China)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; RANTES; TUMOR NECROSIS FACTOR; CCL5 PROTEIN, HUMAN; IL10 PROTEIN, HUMAN; IL2 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; INTERLEUKIN 2;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CYTOKINE BLOOD LEVEL; DISEASE ASSOCIATION; EFFECT SIZE; HUMAN; IN VITRO STUDY; INFLAMMATION; META ANALYSIS (TOPIC); PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STANDARDIZATION; SYSTEMATIC REVIEW; BLOOD; META ANALYSIS; METABOLISM;

C-REACTIVE PROTEIN; CHEMOKINE CCL5; HUMANS; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-2; INTERLEUKIN-6; PARKINSON DISEASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84996939136     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2016.2742     Document Type: Article

References (73)

1. Bhimani R. Understanding the burden on caregivers of people with Parkinson's: A scoping review of the literature. Rehabil Res Pract. 2014; 2014:718527.
2. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368-376.
3. DauerW, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003;39(6): 889-909.
4. Bonuccelli U, Del Dotto P, Rascol O. Role of dopamine receptor agonists in the treatment of early Parkinson's disease. Parkinsonism Relat Disord. 2009;15(suppl 4):S44-S53.
5. Marsden CD. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol. 1994;17(suppl 2):S32-S44.
6. Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Transl Neurodegener. 2015;4:19.
7. Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol. 2007;150(8):963-976.
8. Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science. 2013;339(6116):166-172.
9. Dowlati Y, Herrmann N, SwardfagerW, et al. Ameta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446-457.
10. Miller BJ, Buckley P, SeaboltW, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70(7):663-671.
11. SwardfagerW, Lanctôt K, Rothenburg L, Wong A, Cappell J, Herrmann N. Ameta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry. 2010;68(10):930-941.
12. Masi A, Quintana DS, Glozier N, Lloyd AR, Hickie IB, Guastella AJ. Cytokine aberrations in autism spectrum disorder: A systematic review and meta-analysis. Mol Psychiatry. 2015;20(4):440-446.
13. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 1988;38(8):1285-1291.
14. Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol. 2005;57(2):168-175.
15. Boka G, Anglade P,Wallach D, Javoy-Agid F, Agid Y, Hirsch EC. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett. 1994;172(1-2): 151-154.
16. Mogi M, Harada M, Kondo T, et al. Interleukin-1 β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients. Neurosci Lett. 1994;180(2):147-150.
17. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T. Interleukin (IL)-1 β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett. 1996;211(1):13-16.
18. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994;165(1-2):208-210.
19. Mosley RL, Hutter-Saunders JA, Stone DK, Gendelman HE. Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med. 2012;2(1):a009381.
20. Brodacki B, Staszewski J, Toczyłowska B, et al. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFα, and INFγ concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci Lett. 2008;441(2):158-162.
21. Bu XL,Wang X, Xiang Y, et al. The association between infectious burden and Parkinson's disease: A case-control study. Parkinsonism Relat Disord. 2015;21(8):877-881.
22. Choi C, Jeong JH, Jang JS, et al. Multiplex analysis of cytokines in the serum and cerebrospinal fluid of patients with Alzheimer's disease by color-coded bead technology. J Clin Neurol. 2008;4(2):84-88.
23. Dursun E, Gezen-Ak D, Hanaǧasi H, et al. The interleukin 1α, interleukin 1β, interleukin 6 and α-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease. J Neuroimmunol. 2015;283:50-57.
24. Gruden MA, Yanamandra K, Kucheryanu VG, et al. Correlation between protective immunity to α-synuclein aggregates, oxidative stress and inflammation. Neuroimmunomodulation. 2012;19 (6):334-342.
25. Williams-Gray CH, Wijeyekoon R, Yarnall AJ, et al; ICICLE-PD study group. Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD). Mov Disord. 2016;31(7):995-1003.
26. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6(7):e1000097.
27. Goetz CG, PoeweW, Rascol O, et al; Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease.Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19(9):1020-1028.
28. Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mov Disord. 2002;17(5):867-876.
29. Hedges LV, Olkin I. Statistical Methods for Meta-analysis. New York, NY: Academic Press; 1985.
30. Qin XY, Cao C, Cawley NX, et al. Decreased peripheral brain-derived neurotrophic factor levels in Alzheimer's disease: ameta-analysis study (N=7277) [published online April 26, 2016]. Mol Psychiatry. doi:10.1038/mp.2016.62
31. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127(9):820-826.
32. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
33. Soeken KL, Sripusanapan A. Assessing publication bias in meta-analysis. Nurs Res. 2003; 52(1):57-60.
34. Akil E, Bulut A, Kaplan I, Ozdemir HH, Arslan D, Aluçlu MU. The increase of carcinoembryonic antigen (CEA), high-sensitivity C-reactive protein, and neutrophil/lymphocyte ratio in Parkinson's disease. Neurol Sci. 2015;36(3):423-428.
35. Andican G, Konukoglu D, BozluolcayM, Bayülkem K, Firtiina S, Burcak G. Plasma oxidative and inflammatory markers in patients with idiopathic Parkinson's disease. Acta Neurol Belg. 2012;112(2):155-159.
36. Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW. Association of circulating TNF-α and IL-6 with ageing and parkinsonism. Acta Neurol Scand. 1999;100(1):34-41.
37. Hofmann KW, Schuh AF, Saute J, et al. Interleukin-6 serum levels in patients with Parkinson's disease. Neurochem Res. 2009;34(8): 1401-1404.
38. Hu Y, Yu SY, Zuo LJ, et al. Parkinson disease with REM sleep behavior disorder: features, α-synuclein, and inflammation. Neurology. 2015;84 (9):888-894.
39. Koziorowski D, Tomasiuk R, Szlufik S, Friedman A. Inflammatory cytokines and NT-proCNP in Parkinson's disease patients. Cytokine. 2012;60(3):762-766.
40. Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O. Non-motor symptoms in patients with Parkinson's disease: correlations with inflammatory cytokines in serum. PLoS One. 2012; 7(10):e47387.
41. Mahlknecht P, Stemberger S, Sprenger F, et al. An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes. Proteome Sci. 2012;10(1):71.
42. Pirttila T, Mehta PD, Frey H, Wisniewski HM. α1-Antichymotrypsin and IL-1β are not increased in CSF or serum in Alzheimer's disease. Neurobiol Aging. 1994;15(3):313-317.
43. Rentzos M, Nikolaou C, Andreadou E, et al. Circulating interleukin-15 and RANTES chemokine in Parkinson's disease. Acta Neurol Scand. 2007;116 (6):374-379.
44. Rentzos M, Nikolaou C, Andreadou E, et al. Circulating interleukin-10 and interleukin-12 in Parkinson's disease. Acta Neurol Scand. 2009;119 (5):332-337.
45. Rota E, Bellone G, Rocca P, Bergamasco B, Emanuelli G, Ferrero P. Increased intrathecal TGF-β1, but not IL-12, IFN-γ and IL-10 levels in Alzheimer's disease patients. Neurol Sci. 2006;27 (1):33-39.
46. Scalzo P, Kümmer A, Cardoso F, Teixeira AL. Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance. Neurosci Lett. 2010;468(1): 56-58.
47. Selikhova MV, Kushlinskii NE, Lyubimova NV, Gusev EI. Impaired production of plasma interleukin-6 in patients with Parkinson's disease. Bull Exp Biol Med. 2002;133(1):81-83.
48. Song IU, Kim JS, Chung SW, Lee KS. Is there an association between the level of high-sensitivity C-reactive protein and idiopathic Parkinson's disease? a comparison of Parkinson's disease patients, disease controls and healthy individuals. Eur Neurol. 2009;62(2):99-104.
49. Song IU, Kim YD, Cho HJ, Chung SW. Is neuroinflammation involved in the development of dementia in patients with Parkinson's disease? Intern Med. 2013;52(16):1787-1792.
50. Stypuła G, Kunert-Radek J, Stepień H, Zylińska K, Pawlikowski M. Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with Parkinson's disease. Neuroimmunomodulation. 1996;3(2-3):131-134.
51. Tang P, Chong L, Li X, et al. Correlation between serum RANTES levels and the severity of Parkinson's disease. Oxid Med Cell Longev. 2014; 2014:208408.
52. Gangemi S, Basile G, Merendino RA, et al. Effect of levodopa on interleukin-15 and RANTES circulating levels in patients affected by Parkinson's disease. Mediators Inflamm. 2003;12(4):251-253.
53. Rocha NP, Teixeira AL, Scalzo PL, et al. Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease. Mov Disord. 2014;29(4):527-531.
54. Scalzo P, Kümmer A, Cardoso F, Teixeira AL. Increased serum levels of soluble tumor necrosis factor-α receptor-1 in patients with Parkinson's disease. J Neuroimmunol. 2009;216(1-2):122-125.
55. Cai G, Kastelein RA, Hunter CA. IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-γ when combined with IL-18. Eur J Immunol. 1999;29(9):2658-2665.
56. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev. 2008;226:205-218.
57. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency inmeta-analyses. BMJ. 2003;327(7414):557-560.
58. Sawada H, Oeda T, Umemura A, et al. Baseline C-reactive protein levels and life prognosis in Parkinson disease. PLoS One. 2015;10(7):e0134118.
59. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: A target for neuroprotection? Lancet Neurol. 2009;8(4):382-397.
60. Kortekaas R, Leenders KL, van Oostrom JC, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol. 2005;57 (2):176-179.
61. Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol. 2005;5(8): 629-640.
62. Conroy SM, Nguyen V, Quina LA, et al. Interleukin-6 produces neuronal loss in developing cerebellar granule neuron cultures. J Neuroimmunol. 2004;155(1-2):43-54.
63. Venters HD, Dantzer R, Kelley KW. Tumor necrosis factor-α induces neuronal death by silencing survival signals generated by the type I insulin-like growth factor receptor. Ann N Y Acad Sci. 2000;917:210-220.
64. Feng ZH,Wang TG, Li DD, et al. Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci Lett. 2002;329(3): 354-358.
65. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O'Callaghan JP. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J. 2002;16(11):1474-1476.
66. Deleidi M, Gasser T. The role of inflammation in sporadic and familial Parkinson's disease. Cell Mol Life Sci. 2013;70(22):4259-4273.
67. McCoy MK, Martinez TN, Ruhn KA, et al. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci. 2006; 26(37):9365-9375.
68. Chen H, Zhang SM, Hernán MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol. 2003;60(8): 1059-1064.
69. Wahner AD, Bronstein JM, Bordelon YM, Ritz B. Nonsteroidal anti-inflammatory drugsmay protect against Parkinson disease. Neurology. 2007;69(19):1836-1842.
70. Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology. 2011;76(10):863-869.
71. Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol. 2011;95(4):629-635.
72. Swanson CR, Berlyand Y, Xie SX, Alcalay RN, Chahine LM, Chen-Plotkin AS. Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients. Mov Disord. 2015;30(12):1648-1656.
73. Santos-García D, Mir P, Cubo E, et al; COPPADIS Study Group. COPPADIS-2015 (Cohort of Patients with Parkinson's Disease in Spain, 2015), a global-clinical evaluations, serum biomarkers, genetic studies and neuroimaging-prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression. BMC Neurol. 2016; 16:26.